Contact:
4008465777
Tonghua Dongbao: Clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) approved
Date：2023-12-11
Author：东宝
Views：0
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the notice of approval from the Center for Drug Evaluation of the National Medical Products Administration (CDE) for the clinical trial of its novel THDBH120 injection* (dual GLP-1/GIP receptor agonist).
Keeping up with the global trend in R&D of peptide-based weight-loss and antidiabetic drugs, Tonghua Dongbao is betting on multi-agonist and long-acting novel drugs. As the Company's key novel drug under development, THDBH120 injection is a glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor dual-target agonist. In addition to type 2 diabetes, the Company will explore other indications for THDBH120 injection in the future, such as obesity, so as to tap into new markets and maximize the product value.
The future market of THDBH120 injection is promising. Tirzepatide, the world's first dual GLP-1/GIP receptor agonist of its kind, has seen rapid sales growth since its launch. Tirzepatide (trade name: Mounjaro) was approved for marketing by FDA and EMA in 2022, and its global sales in the first three quarters of 2023 reached USD 2.957 billion. So far, no dual GLP-1/GIP receptor agonist has been approved in China.
About THDBH120 injection (dual GLP-1/GIP receptor agonist)
THDBH120 injection integrates the effects of two incretins, GLP-1 and GIP, into a polypeptide monomer and improves metabolic stability through molecular design, synergistically promoting blood glucose control. It meets the clinical needs of diabetic patients who are no better after treatment with single molecular targets or compounded preparations. THDBH120 injection is expected to become a more long-acting blockbuster drug for the treatment of diabetes.
*Note: The name of the drug product has been changed from "THDBH121 injection" to "THDBH120 injection".
